92 related articles for article (PubMed ID: 6145427)
21. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
23. Clinical review of risperidone.
Chouinard G; Arnott W
Can J Psychiatry; 1993 Sep; 38 Suppl 3():S89-95. PubMed ID: 7504574
[TBL] [Abstract][Full Text] [Related]
24. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study.
Addington DE; Jones B; Bloom D; Chouinard G; Remington G; Albright P
Clin Ther; 1993; 15(5):917-26. PubMed ID: 7505716
[TBL] [Abstract][Full Text] [Related]
25. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
26. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
27. [Attitude of family to neuroleptics].
Angermeyer MC; Matschinger H
Psychiatr Prax; 1999 Jul; 26(4):171-4. PubMed ID: 10457968
[TBL] [Abstract][Full Text] [Related]
28. THE LESSA (Lebanese Short-term Study with Amisulpride) STUDY a Phase IV clinical trial in acutely ill schizophrenic patients.
Baddoura R; Ourgandjian H
J Med Liban; 2004; 52(2):78-85. PubMed ID: 15884686
[TBL] [Abstract][Full Text] [Related]
29. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
[TBL] [Abstract][Full Text] [Related]
30. Meeting everyday challenges: antipsychotic therapy in the real world.
Gorwood P
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S156-62. PubMed ID: 16872807
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostics and therapy of depressive symptoms in schizophrenic patients].
Bottlender R; Hampel H; Sievers M; Möller HJ
MMW Fortschr Med; 2005 May; 147 Spec No 2():59-62. PubMed ID: 15968875
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
Langlois-Thery S; Dollfus S; Lesieur P; Petit M
Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
[TBL] [Abstract][Full Text] [Related]
33. An uncontrolled clinical study with EX 11-582A in the treatment of chronic schizophrenic patients.
Lehmann HE; Ban TA; Deutsch M
Psychopharmacol Bull; 1977 Jul; 13(3):7-9. PubMed ID: 18761
[No Abstract] [Full Text] [Related]
34. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
[TBL] [Abstract][Full Text] [Related]
35. [Clinical effectiveness of isofloxythepin--an open study].
Zapletálek M; Tůma I; Kudrnová K
Cesk Psychiatr; 1985 Aug; 81(4):242-6. PubMed ID: 2864141
[No Abstract] [Full Text] [Related]
36. [Neuroleptic disinhibitory agents].
Ginestet D
Encephale; 1978; 4(5 Suppl):541-5. PubMed ID: 38105
[TBL] [Abstract][Full Text] [Related]
37. [Initial experience with the neuroleptic Zetidoline in hospitalized schizophrenic patients].
Zapletálek M; Libiger J; Tůma I
Cesk Psychiatr; 1983 Apr; 79(2):83-8. PubMed ID: 6134590
[No Abstract] [Full Text] [Related]
38. Pharmacogenic depression among outpatient schizophrenic patients: a failure to substantiate.
Hogarty GE; Munetz MR
J Clin Psychopharmacol; 1984 Feb; 4(1):17-24. PubMed ID: 6141187
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the effect of fluperlapine on the EEG in schizophrenic patients.
Ferber G; Matejcek M; Krebs E; Friedmann R
Neuropsychobiology; 1987; 18(1):43-50. PubMed ID: 2895433
[TBL] [Abstract][Full Text] [Related]
40. [Various methods of overcoming resistance to therapy in childhood and adolescent schizophrenia].
Antropov IuF
Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(10):1522-6. PubMed ID: 6118983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
